ASX, Nasdaq and Media Release

ASX, Nasdaq and Media Release

UPDATE -- Opthea to Participate in November Investor Conferences

Virtual Bell Potter Healthcare Conference, November 18, 2024

Jefferies London Healthcare Conference, November 19, 2024

Melbourne, Australia, and Princeton, NJ, US, November 4, 2024 -- Opthea Limited (ASX/NASDAQ: OPT, Opthea , the Company ), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that management will participate in two investor conferences in November 2024.

Conference details are as follows:

Bell Potter Healthcare Conference

Presentation: Monday, November 18, 2024, 3:00 PM AEDT (Virtual)

Presenter: Frederic Guerard, PharmD, CEO, Opthea

The webcast will be accessible under Events & Presentations in the Investor Relations section of the Company's website, www.opthea.com.

Jefferies London Healthcare Conference 2024

One-on-One Meetings: Tuesday, November 19, 2024

Participant: Frederic Guerard, PharmD, CEO, Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST,NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A monotherapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

Authorized for release to ASX by Frederic Guerard, Pharm D, CEO